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Background: Data generated with the body composition monitor (BCM, Fresenius) show, based on bioimpedance
technology, that chronic fluid overload in hemodialysis patients is associated with poor survival. However, removing
excess fluid by lowering dry weight can be accompanied by intradialytic and postdialytic complications. Here, we
aim at testing the hypothesis that, in comparison to conventional hemodialysis, blood volume-monitored
regulation of ultrafiltration and dialysate conductivity (UCR) and/or regulation of ultrafiltration and temperature
(UTR) will decrease complications when ultrafiltration volumes are systematically increased in fluid-overloaded
hemodialysis patients.
Methods/design: BCM measurements yield results on fluid overload (in liters), relative to extracellular water (ECW). In
this prospective, multicenter, triple-arm, parallel-group, crossover, randomized, controlled clinical trial, we use BCM
measurements, routinely introduced in our three maintenance hemodialysis centers shortly prior to the start of the study,
to recruit sixty hemodialysis patients with fluid overload (defined as ≥15% ECW). Patients are randomized 1:1:1 into UCR,
UTR and conventional hemodialysis groups. BCM-determined, ‘final’ dry weight is set to normohydration weight −7% of
ECW postdialysis, and reached by reducing the previous dry weight, in steps of 0.1 kg per 10 kg body weight, during 12
hemodialysis sessions (one study phase). In case of intradialytic complications, dry weight reduction is decreased,
according to a prespecified algorithm. A comparison of intra- and post-dialytic complications among study groups
constitutes the primary endpoint. In addition, we will assess relative weight reduction, changes in residual renal function,
quality of life measures, and predialysis levels of various laboratory parameters including C-reactive protein, troponin T,
and N-terminal pro-B-type natriuretic peptide, before and after the first study phase (secondary outcome parameters).
Discussion: Patients are not requested to revert to their initial degree of fluid overload after each study phase. Therefore,
the crossover design of the present study merely serves the purpose of secondary endpoint evaluation, for example to
determine patient choice of treatment modality. Previous studies on blood volume monitoring have yielded inconsistent
results. Since we include only patients with BCM-determined fluid overload, we expect a benefit for all study participants,
due to strict fluid management, which decreases the mortality risk of hemodialysis patients.
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The importance of volume control has been recognized
since the early years of hemodialysis [1], but was previ-
ously hampered by the limitations of noninvasive methods
used to estimate the hydration state of hemodialysis
patients [2]. Recently, the body composition monitor
(BCM, Fresenius Medical Care, Bad Homburg, Germany)
was introduced, and prescribed to combine a whole-body
bioimpedance spectroscopy method with an inbuilt
physiologic tissue model [3]. BCM measurements of
volume status were successfully validated against gold
standard determinations of extracellular and intracellular
volume, total body water, fat, fat-free mass and fluid over-
load [4-7]. Hemodialysis patients with fluid overload >15%
extracellular water (ECW), as determined by BCM mea-
surements, were prospectively found to have a markedly
higher mortality risk than patients with <15% ECW
(hazard ratio (HR)=2.1, P=0.003) [8]. These results have
attracted considerable attention in the dialysis community,
and are challenging the concept of interdialytic weight gain
(IDWG) as a proxy for fluid retention [9] and measure of
nonadherence [10]. By contrast, the novel data imply that
reaching the adequate hydration status or ‘dry weight’ post-
dialysis is more beneficial than reducing fluid intake during
the interdialytic interval.
Lowering the dry weight of hemodialysis patients
without increasing treatment time can be accompanied
by intradialytic complications, mostly cramping and
hypotension [11]. Noninvasive hematocrit monitoring
technologies, such as crit-line monitoring, were developed
as early as 1991 on the basis of optical transmission/
optical absorbance [12-15] or ultrasound [16-18] with the
ultimate goal to prevent such complications. Determining
a hematocrit threshold and manipulating ultrafiltration
(UF) rates to maintain the instantaneous hematocrit value
two units below the established hematocrit threshold led
to a twofold reduction in intradialytic symptoms in
hypotension-prone patients [19]. However, various
subsequent trials, including the Crit-Line Intradialytic
Monitoring Benefit (CLIMB) study [20] failed to yield
consistently positive results [21-24], possibly because
there is considerable intra- and inter-individual vari-
ability of the BVM changes [25].
In the CLIMB study, blood volume monitoring (BVM,
for example, crit-line monitoring) was studied as a volun-
tary adjunct to care, and no algorithms, clinical manage-
ment advice or instructions were provided for the
conventionally monitored patients [20]. However, re-
sponse options to BVM have been available since the early
’90s [16] and include feedback regulation of ultrafiltration
[26] based on stored BVM measurements [27] using fuzzy
logic principles [28], and regulation of the dialysate con-
ductivity [29-35]. Feedback control of blood temperature,
for example with the body temperature monitor (BTM,Fresenius) [36-38], is an alternative method to prevent
intradialytic hypotension.
In the present study, we use BCM measurements to de-
termine a patient’s ideal dry weight and do not use BVM as
a diagnostic tool. However, we utilize BVM response
options currently available in modern dialysis machines,
namely, (1) regulation of ultrafiltration and dialysate
conductivity (UCR, Nikkiso Europe GmbH, Hanover,
Germany) and (2) regulation of ultrafiltration (Fresenius)
in those hemodialysis patients with ≥15% ECW, who are
concurrently subjected to systematic increases in ultra-
filtration volume, to reach a final dry weight of normo-
hydration weight −7% of ECW. When using the
Fresenius machines, we simultaneously employ the
BTM to maintain a patient’s original body temperature
(hence UTR means ultrafiltration and temperature
regulation). Our aim is to assess whether UCR and/or
UTR are superior to conventional hemodialysis with re-
spect to frequency of intra- and post-dialytic complica-
tions (primary outcome), and improvement of various
secondary outcome parameters, possibly related to
improved hemodialysis stability and volume status.
Methods/design
Hypothesis
In comparison to conventional hemodialysis, regulation
of ultrafiltration and dialysate conductivity (UCR) and/
or regulation of ultrafiltration and temperature (UTR)
will decrease intra- and post-dialytic complications when
ultrafiltration volumes are systematically increased in
fluid-overloaded hemodialysis patients.
Objectives and outcome measures
The primary objective is to demonstrate superiority of
ultrafiltration and dialysate conductivity regulation
(UCR) and/or ultrafiltration and temperature regulation
(UTR) over conventional hemodialysis, in preventing
intra- and post-dialytic complications, when fluid-
overloaded hemodialysis patients receive systematic fluid
reduction, to reach a final dry weight of normohydration
weight −7% of ECW postdialysis. The primary outcome
measure is the total number of hemodialysis sessions
per patient that were accompanied, intra- or post-dialyti-
cally, by at least one symptom most likely related to fluid
withdrawal (as specified in Table 1), divided by the num-
ber of hemodialysis sessions at risk (as by study protocol:
12 sessions per patient in study phase 1). Both groups,
UCR and UTR, will be compared against the conven-
tional hemodialysis group, and afterward against one an-
other, using the two-sided Student’s t test
The secondary objectives are:
(a).To demonstrate superiority of ultrafiltration and
dialysate conductivity regulation (UCR) and/or
Table 1 Complications related to fluid withdrawa
(1)Intradialytic cramping
(2)Intradialytic hypotension (>40 mmHg SBP) within 30 minutes:
clinically asymptomatic
(3)Intradialytic hypotension (>40 mmHg SBP) within 30 minutes:
clinically symptomatic
(4)Clinically symptomatic intradialytic hypotension: unspecified drop in
SBP
(5)Unspecified intradialytic complication, most likely related to fluid
withdrawal
(6)Patient-reported postdialysis complication, most likely related to fluid
withdrawal
As a consequence of any of the above: dry weight reduction reduced at
subsequent hemodialysis session (yes or no answer). SBP systolic blood
pressure.
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over conventional hemodialysis, in preventing
specific intradialytic complications:
1. intradialytic cramping
2. clinically asymptomatic, intradialytic hypotension
(>40 mmHg drop in systolic blood pressure
(SBP) within 30 minutes)
3. clinically symptomatic, intradialytic hypotension
(>40 mmHg drop in SBP within 30 minutes)
4. clinically symptomatic, intradialytic hypotension
(even if it is not possible to identify a sudden
drop in blood pressure, for example, patients may
slowly move towards low blood pressure values (f.
ex. below 100 mmHg SBP), and report
symptoms)
5. unspecified intradialytic symptoms or events,
which are most likely related to fluid withdrawal
6. patient-reported postdialysis complication, most
likely related to fluid withdrawal (All of the above
also listed in Table 1)
when fluid-overloaded hemodialysis patients receive sys-
tematic fluid reduction, to reach a final dry weight of
normohydration weight −7% of ECW postdialysis. The
secondary outcome measure for objective (a) is the total
number of hemodialysis sessions per patient which were
accompanied by the respective symptom most likely
related to fluid withdrawal (1 to 6), divided by the num-
ber of hemodialysis sessions at risk (as by study protocol:
12 sessions per patient in study phase 1). Both groups,
UCR and UTR, will be compared against the conven-
tional hemodialysis group, and afterward against one
another, using the two-sided Student’s t test.
(b).To demonstrate superiority of UCR and/or UTR
over conventional hemodialysis in allowing patients
to reach a lower body weight, relative to his/her
postdialysis weight at the beginning of study phase
1 (time zero). The secondary outcome measure forobjective (b) is the difference in postdialysis body
weight from time zero to the end of study phase 1,
divided by the postdialysis body weight at time
zero.
Example: if a patient has a postdialysis body weight of
65 kg at time zero (the last hemodialysis session before the
first dry weight reduction), and reaches a postdialysis body
weight of 62 kg at the end of the first study phase, his
difference in body weight will be 65 kg – 62 kg = 3 kg.
Relative to this patient’s postdialysis body weight at time
zero, weight reduction from beginning to end of study
phase 1 will be 3/65*100 = 4.61%.
The relative weight reduction in both groups, UCR and
UTR, will be compared against the conventional
hemodialysis group, and afterward against one another,
using the two-sided Student’s t test.
(c).To assess the amount of sodium transferred to the
patient or withdrawn from the patient during
conventional hemodialysis, UCR and UTR.
The amount of sodium removed during hemodialysis is a
function of the ultrafiltration volume, the effective diffusion
gradient for sodium, and diffusive sodium clearance. The
effective diffusion gradient depends on the plasma water -
dialysate sodium (DNa) difference, and the Gibbs-Donnan
coefficient, the latter being a function of the plasma protein
concentration but also being influenced by other ions in the
dialysate [39,40]. The assumption that sodium removal by
ultrafiltration is equal to the plasma water sodium
concentration, multiplied by the ultrafiltration volume, is a
simplification [41,42]. Electrolyte balances may also be
influenced by the membrane charge [43]. Therefore, the
amount of sodium transferred will be measured on the
dialysate side. Sodium transfer will be calculated from the
difference between the mean sodium concentration in
partially collected, used dialysate and the fresh DNa
concentration, multiplied by the total amount of dialysate
used. Results will be compared to a two-pool sodium model
and parameters of the model will be adjusted using the
measured transfer data. The above described method is not
applicable to the UCR group because the sodium
concentration of fresh dialysate is not kept constant during
treatment. In order to establish the model, we will measure
at least ten patients during three hemodialysis sessions, and
due to the formerly stated, we can only use the dialysate
from patients in the conventional hemodialysis group and in
the UTR group. However, after having established this
model, sodium transfer for all patients - conventional, UTR,
and UCR - can be calculated using this very model.
The amount of sodium transferred to or withdrawn
from the patient will be calculated for each patient,
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here above. The secondary outcome measure for
objective (d), for example, the sodium transferred in
both groups, UCR and UTR, will be compared
against the conventional hemodialysis group, and
afterward against one another, using the two-sided
Student’s t test.
(d).To assess if stricter volume control by conventional
hemodialysis, UCR and/or UTR influences
predialysis serum concentrations of (1) C-reactive
protein, (2) D-dimer, (3) fibrinogen, (4) troponin T,
and (5) N-terminal pro-B-type natriuretic peptide.
These proteins are used as read-outs for
inflammation (1, 2, 3), coagulation (2, 3), and
cardiac function (4, 5) and are routinely determined
at all three participating centers. The secondary
outcome measure for objective (e), for example, the
concentrations of the indicated laboratory
parameters in both groups, UCR and UTR, at time
zero and at the end of study phase 1, will be
compared against the conventional hemodialysis
group, and afterward against one another, using the
two-sided Student’s t test. The individual change in
these parameters, from time zero to the end of study
phase 1, will be compared likewise.
(e).To assess if stricter volume control in fluid-
overloaded patients (using UCR, UTR or
conventional hemodialysis) affects the concentration
of various proteins that might serve as novel
biomarkers (including high-density lipoprotein
(HDL)-associated surfactant protein B; HDL-
associated serum amyloid A; HDL-associated apoC-
II; plasma tryptophan; plasma choline; plasma
trimethylamine-N-oxide; and plasma endotoxin).
We have recently discovered that various proteins, including
those mentioned here above, may render HDL dysfunctional,
in hemodialysis patients [44]. Especially with surfactant, we
suspect an association with fluid overload. Moreover, plasma
tryptophan, plasma choline, and plasma trimethylamine-N-
oxide are markers of end-stage renal disease [45]. Since one
or several of these proteins or molecules might serve as
novel biomarkers, we would like to use the context of the
present trial to establish diagnostic assays and analyze
potential changes in the serum concentration of these
proteins, before and after fluid removal.
Endotoxin, found in the cell membranes of gram-negative
bacteria, is a biomarker representing the gut flora. Endotoxin
has been shown to be associated with inflammation,
nutritional status and even mortality in hemodialysis patients
[46]. An incremental rise in endotoxin levels has been shown
along with the progression of chronic kidney disease, and
especially initiation of hemodialysis [47]. It has been
suggested that hemodialysis patients might have highendotoxin levels in the blood due to repeated bacterial
translocation from the gut during hemodialysis, secondary to
intradialytic changes in blood pressure and/or tissue
perfusion. An association with chronic fluid overload has not
yet been established, but might be suspected, as a
consequence of higher ultrafiltration rates and thus
decreased intradialytic stability. Here, we will measure
endotoxin levels with an amebocyte limulus assay in all study
patients, at time zero and at the end of study phase 1.
The secondary outcome measure for objective (f ),
for example HDL-associated serum amyloid A in
both groups, UCR and UTR, at time zero and at
the end of study phase 1, will be compared
against the conventional hemodialysis group, and
afterward against one another, using the two-sided
Student’s t test. The individual change in these
parameters, from time zero to the end of study
phase 1, will be compared likewise. The results of
this secondary endpoint analysis will be published
separately from the clinical results of the present
study.
(f ).To assess if stricter volume control in fluid-
overloaded patients (using UCR, UTR or
conventional hemodialysis) affects quality of life
measures. The secondary outcome measures for
objective (g) are the mental component
summary (MCS) and physical component
summary (PCS) derived from the Kidney Disease
Quality of Life Short Form (KDQOL-SFTM) [48].
The scale of both summary scores is 0 to 100
(higher indicating better quality of life). MCS
and PCS in both groups, UCR and UTR, at
time zero and at the end of study phase 1, will
be compared against the conventional
hemodialysis group, and afterward against one
another, using the two-sided Student’s t test. The
individual change in these parameters, from
time zero to the end of study phase 1, will be
compared likewise.
(g).To demonstrate superiority of UCR and/or UTR
over conventional hemodialysis in reducing
dialysis complications when previously fluid-
overloaded patients are entering phase 2 and
phase 3 of the presented study. In study phases
2 and 3, patients either have to reduce their dry
weight further, or else have to maintain their
newly reached dry weight. The secondary
outcome measures for objective (h) are
potentially all of the items described here above,
and will be compared against the conventional
hemodialysis group, and afterward against one
another, in the same fashion as described here
above.
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will be chosen by the patients at the end of the
study. The choice of treatment will be compared as
follows: (1) number of patients choosing UCR
treatment against number of patients choosing
conventional treatment; (2) number of patients
choosing UTR treatment against number of patients
choosing conventional treatment; (3) number of
patients choosing UCR treatment against number of
patients choosing UTR treatment. The statistical test
for analyses (1), (2) and (3) will be the two-sided chi
square test, for each analysis.
Superiority definition
For all objectives listed, superiority will be assumed if a
statistically significant difference between one group ver-
sus another group can be determined. The significance
level (alpha) will be set at 0.05. With regard to the primary
endpoint, according to our sample size calculation (see
below), this study is suited to detect a minimal difference
of 10% between groups, if the occurrence of intradialytic
symptoms in the conventional group is similar as in a
previous study [20].
Study design
This study is a prospective, multicenter, triple-arm, parallel-
group, crossover, randomized, controlled clinical trial. The
crossover design serves the purpose of analyzing, in an
exploratory form, the secondary endpoints (g) and (h), but
does not contribute to the power of the primary endpoint
analysis. The reason is that a meaningful crossover analysis
would have necessitated that patients revert back to fluid
overload, prior to their entering into a new treatment
phase; a procedure that we considered unethical.
Study setting and organizational details
Patient recruitment and follow-up are conducted at the
maintenance hemodialysis facilities of the Medical
University of Vienna, the Sozialmedizinisches Zentrum
Süd in Vienna and the Krankenhaus Donauspital SMZ
Ost in Vienna. Baseline demographics from the Medical
University of Vienna hemodialysis facility [49] compare
very well to international dialysis demographics, as in our
recent analysis using data from the Dialysis Outcomes and
Practice Patterns study (DOPPS) [50]. Demographics from
the other two hemodialysis facilities are not available prior
to the start of this study.
The study flow chart is depicted in Figure 1. The in-
clusion criteria are (1) hemodialysis vintage >3 months,
(2) fluid overload ≥15% ECW predialysis, as determined
by BCM measurement, after one of the two midweek
interdialytic intervals, and (3) informed consent of the
patient. There are no specific exclusion criteria, other
than the reciprocal inclusion criteria, and those criteriaimplied by good clinical practice and the Declaration of
Helsinki (for example, exclusion of minors and of men-
tally disabled patients). Patients will only be included
once. Monitoring of the participants will be ended after
the participants’ completion of the study phases.
For patients who are willing to participate in the
study, dry weight reduction is prescribed according to
a previously published algorithm [11] described here
below. Block randomization takes place in a 1:1:1
ratio into study group A (UCR), study group B (UTR)
or study group C (conventional hemodialysis). The
randomization code is developed using an internet-
based randomization tool [51] and is not revealed to parti-
cipants or investigators. We are stratifying by hemodialysis
center, thus there is a different randomization list for each
center.
UCR and UTR cannot be applied without previous
knowledge of a particular patient’s blood volume changes
during the hemodialysis session, which have been shown
to be variable, intra- and inter-individually [25]. Therefore,
UCR and UTR require a run-in period, which has to be
performed every time that UCR and/or UTR are being
used. Completion of the run-in period is judged successful
for UCR, respectively UTR, if the responsible technicians
from Nikkiso, respectively Fresenius, have set the blood
volume corridors, respectively have determined the critical
point, for adequate use of UCR, respectively UTR. No more
than a maximum of twelve, respectively six, hemodialysis
sessions are provided to the Nikkiso, respectively Fresenius,
technicians, as previously agreed.
Baseline is defined as the day of the BCM measure-
ment. Time zero is defined, for every study phase, as the
first hemodialysis session with dry weight reduction after
the run-in phase. After completion of the first study
period (twelve hemodialysis sessions for all three
groups), patients crossover to the respective other study
arms, as prespecified at the time of randomization.
There is no explicit washout period between the first
study phase and any of the subsequent study phases.
However, another run-in period is required for the non-
conventional treatment arms, before study phases 2 and
3. BCM measurements to adjust or re-prescribe dry
weight reduction will be performed before every run-in
period, and shortly before time zero of every study
phase. If there is reason to believe that patients may
have a change in their dry mass during the study period
(for example, patients who are hospitalized or who
change their diet), BCM measurement will be repeated,
and the dry weight adjusted accordingly.
Study interventions
This study does not interfere with the principle of best
practice hemodialysis treatment, which has been described
elsewhere [52]. Patients with hemodiafiltration protocols
Hemodialysis patients, vintage 










- Rapid removal of excess fluid




Month 0 1 2 3
Cross-over Cross-over
Figure 1 Study flow chart. The duration of the crossover period will depend on the run-in phase required for the next study arm: up to six
hemodialysis sessions for regulation of ultrafiltration and temperature (UTR), and up to twelve hemodialysis sessions for regulation of ultrafiltration
and dialysate conductivity (UCR), no run-in required for conventional hemodialysis. BCM, body composition monitor; ECW, extracellular water.
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the duration of the study.Dry weight reduction
The BCM measurement for fluid overload is provided in
kilograms and percentage of ECW. A patient’s new dry
weight is calculated as follows: (Predialysis body weight –
(fluid overload+ 7% ECW)). Thus it is the normohydration
weight −7% ECW, and serves as the new, BCM- deter-
mined, ideal, or ‘final’ dry weight. In order to reach this
‘final’ dry weight, the patient’s previous dry weight is
decreased as previously described in the ‘Dry-Weight Re-
duction in Hypertensive Hemodialysis Patients’ (DRIP) trial
[11]: by 0.1 kg per 10 kg body weight at every hemodialysis
session until the final dry weight is reached or any intradia-
lytic complications (listed in Table 1) may occur.
An exemplary dry weight reduction scenario is provided
in Figure 2. In the event of the first intradialytic complica-
tion, standardized clinical interventions take place as listed
in Table 2, and the dry weight of the ongoing hemodialysis
session is re-adjusted to the dry weight of the previous
hemodialysis session. At the subsequent hemodialysis
session, the dry weight is prescribed as 50% of the previ-
ous, additional fluid removal, and all further dry weight
reductions are prescribed accordingly. In the event of the
second intradialytic complication, standardized clinical
interventions take place, and the dry weight at the on-
going hemodialysis session is re-adjusted to the dry weight
of the previous hemodialysis session, as before. At the
subsequent hemodialysis session, fluid removal is further
reduced by 50% of the corrected, additional fluid removal,
or to a minimum of 200 g (whatever occurs first, depend-
ing on the overall weight of the patient). In the event of a
third intradialytic complication, standardized clinical
interventions take place, and the dry weight at the on-
going hemodialysis session is re-adjusted to the dry weight
of the previous hemodialysis session, as before. No further
attempts are made to reduce the dry weight during thisstudy period, unless the patient did not yet reach reduc-
tion steps of 200 g.
Justification for the duration of the study phase: 12
hemodialysis sessions per study phase imply that, if
regulated ultrafiltration can prevent intra- and post-
dialytic complications, a 70 kg patient is, in theory, able
to remove as much as 12 × 700 g = 8.2 L of excess fluid
within one study phase. Therefore, we expect that for
the great majority of patients, we would theoretically be
capable of removing all excess fluid within one study
phase.
UCR and UTR versus conventional hemodialysis
The principle difference between the two techniques
under investigation, UCR and UTR, in comparison to the
standard treatment (conventional hemodialysis), is that
the ultrafiltration rates in the UCR and UTR groups are
variable, and - usually - increased at the beginning of the
dialysis treatment, when blood volume slopes are flatter,
indicating that refilling takes place from the interstitial to
the intravascular compartment. By contrast, ultrafiltration
rates in the conventional hemodialysis group are constant,
and can be calculated by dividing the total amount of
ultrafiltration by the dialysis treatment time.
UCR: dialysis machines from Nikkiso which allow UCR
are currently in use at all three participating centers. After
recording several (up to 12) hemodialysis sessions, an
individual BVM reference corridor - above and below the
typical blood volume slope - is determined for every pa-
tient. Ultrafiltration as well as dialysate conductivity regu-
lation are started from there on until the end of this study
period. In addition to variable ultrafiltration rates, the con-
ductivity component of UCR - through intradialytic
changes in dialysate sodium - is aimed at further increas-
ing the refilling process, whenever blood volume slopes
indicate that this is necessary.
UTR: dialysis machines from Fresenius which allow
UTR are currently in use at all three participating centers.
After recording several (up to six) hemodialysis sessions,
Run-in: 12 HD-sessions
Predialysis weight 64.5 kg
BCM-detected fluid overload 5 L predialysis (=25.5% ECW)
Ideal dry weight 58.1 kg (64.5 kg - 5 kg - [7% × ECW])
Patient randomized to UCR - Conventional - UTR
UCR session 1: Prescribed dry weight 61.4 kg
No complications
UCR session 2: Prescribed dry weight 59.8 kg
No complications
UCR session 3: Prescribed dry weight 59.2 kg
Cramp 1. Session ends with 59.8 kg 
UCR session 4: Prescribed dry weight 59.5 kg
No complications
UCR session 5: Prescribed dry weight 59.2 kg
UCR session 6: Prescribed dry weight 59.3 kg
No complications
UCR session 7: Prescribed dry weight 59.1 kg
No complications
UCR session 8: Prescribed dry weight 58.9 kg
No complications
UCR session 9: Prescribed dry weight 58.7 kg
No complications
UCR session 10: Prescribed dry weight 58.5 kg
Cramp 2. Session ends with 59.5 kg 
No complications
UCR session 11: Prescribed dry weight 58.3 kg
No complications
UCR session 12: Prescribed dry weight 58.1 kg
Figure 2 An exemplary dry weight reduction scenario.
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determined. Above this point, the machine may increase
ultrafiltration rates during the beginning of the hemodia-
lysis session (as by the inbuilt ultrafiltration regulation
device). When the critical point is approached, the ma-
chine decreases ultrafiltration rates, to avoid intradialytic
complications. Ultrafiltration and temperature regulation
(by activating the BTM in the temperature control mode)
is started from there on until the end of this study period.









Cramping 20 mL NaCl
(1 M)*
















Unspecified according to doctor's order
*5.85% weight/volume. IDH intradialytic hypotension, M molar, NaC1 sodium
chloride, SBP systolic blood pressure.
At the occurrence of symptoms, ultrafiltration is decreased and dry weight
adapted, as per the study’s protocol.the body temperature constant, and thereby thought to
increase intradialytic stability by preventing overheating
and thus vasodilation.
Conventional hemodialysis: in the conventional dialysis
arm, we do not allow changes in dialysate temperature,
but continue with the dialysate temperature of the
patient’s last treatment. We also do not allow changes in
the DNa prescription from the patient’s last treatment and
changes in other aspects of the dialysate fluid composition
(this also applies to the UCR and UTR study arms).
Other than ‘intelligent’ regulation of ultrafiltration, the
potential advantage of UCR and/or UTR over conven-
tional hemodialysis is that the dialysis machine alarm goes
off in the case that the blood volume slope of the patient
during a regulated treatment approaches the corridors
(UCR/critical points (UTR)) set for that patient. The dialy-
sis nurse then has the possibility to overrule this alarm, or
to decrease and/or interrupt the total ultrafiltration
prescribed for that particular treatment. Since the aim of
UCR and UTR is to decrease dialysis complications,
nurses are instructed never to overrule an alarm, but to
decrease and/or interrupt the prescribed ultrafiltration.
Antihypertensives
Antihypertensives are withdrawn as in a previous study on
dry weight reduction [11], starting one week prior to the
first hemodialysis session with reduced dry weight. Alpha
and beta blockers are withdrawn first, followed by calcium
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aldosterone system last. The accepted systolic blood pres-
sure during the course of the patient’s antihypertensives
withdrawal phase shall generally not surpass 200 mmHg.
Data retrieval and data recording
Intra- and post-dialytic complications (primary outcome
parameter) as specified in Table 1 are recorded on the
patient’s case report form, and filled out at every
hemodialysis session. Secondary outcome parameters: the
body weight reached at the end of every hemodialysis
session is recorded in the patient’s case report form.
Residual renal function is assessed by measurements of
24-hour urine. Quality of life forms are kept in paper for-
mat and analyzed using MS Excel 2003. All nonexperi-
mental laboratory data are extracted from the patients’
hospital records and analyzed separately from the dialysis-
related outcomes using MS Excel 2003.
Definition of intradialytic and postdialytic complications
The list of intradialytic complications was chosen in
close analogy to a list of secondary outcome measures in
the CLIMB study (Table 4 in [20]), and to the DRIP trial
(Supplementary Table 1 in [11]). As an operational defi-
nition of what is ‘clinically symptomatic’, we specify that,
nausea, dizziness, vomiting, or any other symptom that
the patient may report, if it is most likely related to fluid
withdrawal, shall be judged as ‘clinically symptomatic’.
Based on our dialysis experience and using the DRIP trial
reports as a basis [11], we preclude that besides cramping,
intradialytic hypotension is the major obstacle in intensified
fluid withdrawal, since hospitalizations - also related to
vascular access problems - are dealt with in the analysis of
serious adverse events. There are no measurements taken
against intradialytic hypertension during the course of the
study, unless specifically ordered by the responsible physi-
cians, based on individual patient needs.
Informed consent
The investigator explains the nature of the study, its pur-
pose, procedures, expected duration, and the potential
risks and benefits associated with study participation along
with any discomfort that may be expected. Patients are
informed about the strict confidentiality of their subject
data, but also that their medical records may be reviewed
for trial purposes by authorized individuals other than
their treating physician. Each subject is informed that
study participation is voluntary and withdrawal is possible
at any time during the study period. Withdrawal does not
prejudice the subject’s subsequent care. Subjects are given
time to read and understand the statements before signing
consent and dating the document. Subjects receive a copy
of the signed written statement and the original copy of
the informed consent is stored in the investigator studyfiles. No subject is entered into the study until informed
consent has been obtained.
Safety assessments
Safety assessments include the monitoring and recording
of all adverse events (AE), including serious adverse
events (SAE). An AE is any undesirable experience asso-
ciated with the use of a medical product or procedure in
a patient. An SAE is defined as any untoward medical
occurrence that, at any dose, results in death, is life-
threatening, requires inpatient hospitalization or pro-
longation of existing hospitalization, or results in persist-
ent or significant disability/incapacity. The most probable
AEs caused by dry weight reduction are cramps and
hypotension. The expected intra- and post-dialytic symp-
toms are provided in Table 1. The most probable serious
adverse events caused by dry weight reduction are
vascular-access-related hospitalizations, and aggravated
consequences of postdialysis hypotension, such as frac-
tures due to falling.
Quality control
Execution of the three techniques under investigation is
crucial. Evaluation of the success of UCR and UTR will be
evaluated at the end of the first study phase for all avail-
able treatments and will include at least the following
parameters:
– Availability of a reference line for the setting of
corridors (UCR) critical values (UTR) during the
run-in phase. Specifically, the number of treatments
during the run-in phase with an available reference
line will be reported per patient, and per all of the
treatments during the run-in phase.
– Delayed start of UCR/UTR during the study phases.
Specifically, the number of treatments during the
study phase with a delayed start (>10 minutes) of
UCR/UTR will be reported per patient, and per all
of the treatments during the study phase.
– Delayed input of the ultrafiltration goal during the
study phase. Specifically, the number of treatments
during the study phase with a delayed input of the
ultrafiltration goal (>10 minutes) will be reported
per patient, and per all of the treatments during the
study phase.
– Incorrect input of the ultrafiltration goal during the
study phase. Specifically, the number of treatments
during the study phase with an incorrect input of
the ultrafiltration goal will be reported per patient,
and per all of the treatments during the study phase.
– Inadequate display of the ultrafiltration rate and
conductivity during the study phase. Specifically, the
number of treatments during the study phase with
an inadequate display of the ultrafiltration rate and
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per patient, and per all of the treatments during the
study phase.
Statistical analysis plan
The statistical analysis plan (SAP) provides full details
regarding the analyses, the data display, and the algo-
rithms to be used for data derivations. The SAP includes
the definition of major and minor protocol deviations,
which will be identified by medically trained staff before the
study closure. Safety and tolerability are analyzed descrip-
tively. Safety analysis is performed on the intention-to-treat
(ITT) population. All secondary endpoint analyses are ex-
ploratory in nature.
Sample size calculation: for the primary endpoint ana-
lysis, we will assess the differences in intradialytic complica-
tions between the three study groups, only during the first
study phase. Based on a typical occurrence of 0.14 dialysis-
related complications per patient-day at risk in the conven-
tional hemodialysis group [20], two-sided testing and an
expected standard deviation of 10%, an alpha=0.05 and a
beta=0.2, a sample size of 17 patients per group was deter-
mined to detect a minimum difference of 10% between
groups. The UCR and UTR groups will be tested against
the conventional hemodialysis control group, and afterward
against one another. We expect a drop-out rate of approxi-
mately 10%. Individuals who do not complete the study
cannot be replaced, because we do not include patients
with hemodialysis vintage <3 months, and all patients who
qualify for the study are asked to participate after the initial
BCM measurement at all three centers. Thus, the study
sample was determined to consist of 60 patients with ECW
≥15%, by BCM measurement. If patients are lost to follow-
up, they will be excluded from the analysis
Two different analysis sets are defined for safety and
efficacy, respectively. The efficacy of UCR and UTR will
be assessed in all subjects who received the study
method (at least once) and did not violate the protocol
in a way that might affect the evaluation of the effect of
the study method on the primary objective, that is, with-
out major protocol violations. The per-protocol set is
employed in the analysis of efficacy variables. The safety
analysis set includes subjects who were randomized and
received at least one study method (modified intention-
to-treat). The safety set is employed in the analysis of
tolerability and safety variables. Statistical analysis is per-
formed with SAS.
Approval of the ethics committee and the regulatory
authority
The trial is performed in accordance with the Declaration
of Helsinki. It subscribes to the principles outlined in the
most recent version of the International Conference on
Harmonization on Good Clinical Practice. Approval wasobtained from the ethics committee of the Medical
University of Vienna (EK number 365/2011) and from the
ethics committee of the City of Vienna (EK 11-222-1211).
The study has also been registered in a public clinical trial
database (Identifier Number NCT01416753, Clinical-
Trials.gov).
Discussion
Recent data show prospectively that fluid control based
on BCM measurements and proper adjustment of dry
weight is feasible [53]. Moreover, normohydrated
patients from a German hemodialysis facility did not
have a higher multivariate-adjusted, all-cause mortality
risk than patients undergoing ‘long, slow hemodialysis’
in Tassin, France [54]. Last, the first prospective experi-
ences with the intervention of BCM-based correction of
volume status (for example, lower dry weight prescrip-
tion) support the mortality benefit of normohydration,
shown in the previous association study, where fluid sta-
tus was assessed once, using BCM, and patients were
thereafter followed over three and a half years [8] As a
consequence, we expect a direct benefit for all patients
participating in this study, because lower dry weight will
be prescribed in all three study groups.
The results of the CLIMB study [20], as well as experi-
ences from previous clinical trials, have indicated that BVM
is complicated, and have made its use controversial. For
example, Andrulli et al. found no critical BVM level for the
appearance of symptomatic hypotension in either normo-
tensive, hypotension-prone or hypertensive patients [21].
On the contrary, Barth et al., upon using an ultrasonic
method for BVM, demonstrated an individual relative
blood volume limit for nearly all patients, with only narrow
variability in most patients prone for intradialytic morbid
events [22]. The results of Tonelli et al. suggested in
patients with acute renal failure that BVM and rate of
change in BVM slopes did not predict hypotension and
were not correlated with mean arterial pressure or SBP
[23]. And finally, Mitra et al. observed that the relative
blood volume decline during ultrafiltration switched from
exponential to linear decay, probably indicating vascular
refilling, and suggesting that BVM should move away from
linearity [24]. The present study, however, by using prespe-
cified response options to BVM is intended to overcome
these previous controversies.
Withdrawal of antihypertensives, in order to reach
lower dry weight, may, to some dialysis care takers, seem
unethical. However, blood pressure treatment in
hemodialysis patients is highly controversial. Although
blood pressure control may be the most extensively
studied area in dialysis research, widely accepted propo-
sitions for the treatment of hypertension are still missing
[55,56], mainly because epidemiologic studies have failed
to incriminate hypertension as a cardiovascular risk
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shown to yield some mortality benefit [58,59], but data
from single centers in Uruguay [60], United Kingdom
[61], Turkey [62] and Tassin, France [63] have consistently
demonstrated that strict volume control with relatively
low postdialysis dry weight targets can fully normalize the
blood pressure in a great majority of hemodialysis
patients. In fact, hypertension control without antihyper-
tensive medication is actually the strongest predictor of
survival in hemodialysis patients [64].
Therefore, it is ethical to withdraw antihypertensives in
order to reach the adequate dry weight target, and this
approach has been used before, in the DRIP trial, which
did not include patients based on bioimpedance-based de-
tection of fluid overload, but based on hypertension [11].
The mortality risk for the hemodialysis population - in ob-
servational studies - does not begin to rise before very
high SBP values of 200 mmHg are reached [65,66]. How-
ever, we intend not to generally accept that the SBP during
the course of the patient’s antihypertensives withdrawal
phase surpasses 200 mmHg.
We have recently shown that higher DNa prescriptions
are associated with IDWG, but not with worse outcomes,
and that predialysis serum sodium concentrations correl-
ate inversely with mortality risk [49,67]. Among secondary
outcome parameters, principal emphasis will be placed on
a measurement of intradialytic sodium balance (listed as
secondary objective (c)). This analysis is necessary, as
there is only one previous publication, which estimated,
but did not measure sodium transfer through positive
dialysate-to-serum sodium gradients [68]. The results of
our investigation may help dialysis physicians in their
decision concerning the dialysate sodium prescription, be-
cause they will be able to anticipate which amount of
sodium is transferred during hemodialysis.
As it has been shown that increased cardiovascular
biomarkers such as N-terminal pro-B-type natriuretic
peptide, D-dimer and troponin T are strongly correlated
with inflammation as well as higher cardiovascular mor-
tality in hemodialysis patients [69-71], it will be impor-
tant to assess whether systematic dry weight reduction
improves the chronic inflammatory state associated with
hemodialysis. Combining BCM-based fluid status assess-
ment with UCR and/or UTR-guided hemodialysis, and
simultaneous monitoring of these biomarkers, can po-
tentially show changes in the individual patient’s cardio-
vascular risk profile.
Role of dialysis caretakers; subjectivity: dialysis nurses
must be reminded that it is not in the best interest of
the patients enrolled in the BVM-Reg study to have fluid
withdrawn ‘no matter what’. This is also the reason why
we created symptom category (5) (in Table 1), the ‘un-
specified intradialytic complication’, and category (6), the
‘patient-reported postdialysis complication’, both ‘mostlikely related to fluid withdrawal’. These categories shall
ensure that enrolled patients are maximally protected
from discomfort, since they can report necessary occur-
rences, even postdialysis. In consequence, fluid with-
drawal rates are reduced at the subsequent hemodialysis
sessions.
Based on our working experience, the great majority
of dialysis nurses are aware of the importance of
symptom-free hemodialysis sessions, since discomfort is
almost always reported to the nurses first. However, how
can it be ensured that patients are monitored in the
same way? It is impossible to rate the subjective opinion
of the patient and his/her primary dialysis caretaker
regarding the need to interrupt the fluid withdrawal,
using the reported category (5). In addition, it would
have been very unrealistic to successfully blind the treat-
ment (UCR, UTR, conventional hemodialysis). The lack
of blinding, in combination with the above-mentioned
subjectivity of patients and nurses, can introduce bias
into the study. By instructing dialysis caretakers to re-
main as objective as possible toward the treatments
under investigation, we anticipate that our study will still
yield informative results.
In conclusion, the present study will test the hypothesis
that UCR and/or UTR may lead to fewer complications,
intra- and post-dialytically, when hemodialysis patients
with fluid overload ≥15% ECW receive systematic, and
presumably optimal reduction of their dry weight (to the
normohydration weight −7% of ECW postdialysis). To the
best of our knowledge, this is the first study that combines
bioimpedance measurements for assessment of volume
status and BVM response options. As a consequence,
patients may benefit from two entirely unrelated concepts
in modern fluid management, with potential impact not
only on intradialytic stability, but also dialysis-associated
factors such as residual renal function, inflammation, and
quality of life. Ultimately, applying the dialysis treatment
that proves superior in the present study may translate
into improved dialysis outcomes.
Trial status
At the time of manuscript submission, the present study
- overall - is still recruiting participants (ClinicalTrials.
gov, NCT01416753). While participants are being
recruited at the maintenance hemodialysis facility of the
Sozialmedizinisches Zentrum Süd in Vienna, the study is
ongoing at the hemodialysis facility of Krankenhaus
Donauspital SMZ Ost in Vienna, and at the hemodialysis
facility of the Medical University of Vienna.
Abbreviations
BCM: Body composition monitor; BTM: Body temperature monitor;
BVM: Blood volume monitoring; CLIMB: Crit-Line Intradialytic Monitoring
Benefit (study); DRIP: Dry-Weight Reduction in Hypertensive Hemodialysis
Patients (trial); DNa: Dialysate sodium; DOPPS: Dialysis Outcomes and Practice
Hecking et al. Trials 2012, 13:79 Page 11 of 12
http://www.trialsjournal.com/content/13/1/79Patterns Study; ECW: Extracellular water; HDL: High-density lipoprotein;
HR: Hazard ratio; IDH: Intradialytic hypotension; IDWG: Interdialytic weight
gain; M: Molar; MCS: Mental component summary; NaCl: Sodium chloride;
PCS: Physical component summary; SAE: Serious adverse event; SBP: Systolic
blood pressure; UF: Ultrafiltration; UCR: Regulation of ultrafiltration and
dialysate conductivity; UTR: Regulation of ultrafiltration and temperature.
Competing interests
This academic study is sponsored by the Medical University of Vienna,
Austria. The authors received an unrestricted research grant from Nikkiso Ltd.
with no limits on publication and declare that they have otherwise no
competing interests.
Acknowledgements
We thank Peter Wabel and Friedrich K. Port for revising the present
manuscript and advising us on several aspects of the study protocol, in
particular BCM-measurements (Peter Wabel) and aspects related to dialysis
outcomes, sodium and hypertension (Friedrich K. Port). We also thank nurses
Peter Klotz, Werner Mayer and Josef Schwarzmann, for excellent advice
concerning the technical feasibility of this study.
Author details
1Department of Internal Medicine III, Nephrology and Dialysis, Medical
University of Vienna, Währinger Gürtel 18-20, Vienna 1090, Austria. 2Malerweg
12, Köstenberg9231, Austria. 3Nikkiso Europe GmbH, Beneckealle 30,
Hanover30419, Germany. 4Sozialmedizinisches Zentrum Süd, Kaiser-Franz-
Josef Spital, 1st Medical Department, Dialysis, Kundratstrasse 3Vienna1100,
Austria. 5Sozialmedizinisches Zentrum Ost, Donauspital, 3rd Medical
Department, Dialysis, Langobardenstrasse 122, Vienna1220, Austria.
Authors’ contributions
MH, MA and MS are responsible for all aspects of this trial; in particular, they
designed the study, wrote and revised the manuscript, are registering study
patients and are surveying the study at the Chronic Hemodialysis Facility 1
of the Medical University of Vienna. WW and TR are surveying patients at the
Chronic Hemodialysis Facility 2 of the Medical University of Vienna, and
revised the present manuscript. JW, MH and TW designed the secondary
endpoint analyses listed under (f), and revised the present manuscript. H-DP
contributed intellectually to all technical aspects of this study, designed the
secondary endpoint analysis listed under (d), and revised the present
manuscript. PJ advised us on, and planned the technical aspects of UCR, and
also wrote the part on quality control. IE, KL-T, and ME are registering and
surveying patients at the hemodialysis facility of Sozialmedizinisches
Zentrum Süd. GP and RK-B are registering and surveying patients at the
hemodialysis facility of Krankenhaus Donauspital SMZ Ost. WHH and GS-P
planned and revised the study protocol, as well as the present manuscript.
All authors read and approved the final manuscript.
Received: 21 January 2012 Accepted: 8 June 2012
Published: 8 June 2012
References
1. Scribner BH, Buri R, Caner JE, Hegstrom R, Burnell JM: The treatment of
chronic uremia by means of intermittent hemodialysis: a preliminary
report. Trans Am Soc Artif Intern Organs 1960, 6:114–122.
2. Franz M, Pohanka E, Tribl B, Woloszczuk W, Horl WH: Living on chronic
hemodialysis between dryness and fluid overload. Kidney Int Suppl 1997,
59:S39–42.
3. Wabel P, Chamney P, Moissl U, Jirka T: Importance of whole-body
bioimpedance spectroscopy for the management of fluid balance. Blood
Purif 2009, 27:75–80.
4. Moissl UM, Wabel P, Chamney PW, Bosaeus I, Levin NW, Bosy-Westphal A,
Korth O, Muller MJ, Ellegard L, Malmros V, Kaitwatcharachai C, Kuhlmann
MK, Zhu F, Fuller NJ: Body fluid volume determination via body
composition spectroscopy in health and disease. Physiol Meas 2006,
27:921–933.
5. Moissl U, Bosaeus I, Lemmey A, Hovgesen S, Wabel P, Chamney PW, Bosy-
Westphal A, Korth O, Mueller MJ, Renders L, Ellegard L, Malmros V, Fuller NJ:
Validation of a 3 C model for determination of body fat mass. J Am Soc
Nephrol 2007, 18:257A.6. Moissl U, Wabel P, Chamney PW, Renders L, Bosy-Westphal A, Korth O,
Müller MJ: Validation of a bioimpedance spectroscopy method for the
assessment of fat free mass. NDT plus 2008, 1(suppl 2):ii215.
7. Passauer JMH, Schleser A, Leicht J, Pucalka K: Evaluation of clinical dry
weight assessment in haemodialysis patients by bioimpedance-
spectroscopy. J Am Soc Nephrol 2007, 18:256A.
8. Wizemann V, Wabel P, Chamney P, Zaluska W, Moissl U, Rode C, Malecka-
Masalska T, Marcelli D: The mortality risk of overhydration in
haemodialysis patients. Nephrol Dial Transplant 2009, 24:1574–1579.
9. Kalantar-Zadeh K, Regidor DL, Kovesdy CP, Van Wyck D, Bunnapradist S,
Horwich TB, Fonarow GC: Fluid retention is associated with cardiovascular
mortality in patients undergoing long-term hemodialysis. Circulation
2009, 119:671–679.
10. Saran R, Bragg-Gresham JL, Rayner HC, Goodkin DA, Keen ML, Van Dijk PC,
Kurokawa K, Piera L, Saito A, Fukuhara S, Young EW, Held PJ, Port FK:
Nonadherence in hemodialysis: associations with mortality,
hospitalization, and practice patterns in the DOPPS. Kidney Int 2003,
64:254–262.
11. Agarwal R, Alborzi P, Satyan S, Light RP: Dry-weight reduction in
hypertensive hemodialysis patients (DRIP): a randomized, controlled trial.
Hypertension 2009, 53:500–507.
12. Steuer RR, Harris DH, Weiss RL, Biddulph MC, Conis JM: Evaluation of a
noninvasive hematocrit monitor: a new technology. Am Clin Lab 1991,
10:20–22.
13. Mancini E, Santoro A, Spongano M, Paolini F, Rossi M, Zucchelli P:
Continuous on-line optical absorbance recording of blood volume
changes during hemodialysis. Artif Organs 1993, 17:691–694.
14. Paolini F, Mancini E, Bosetto A, Santoro A: Hemoscan: a dialysis machine-
integrated blood volume monitor. Int J Artif Organs 1995, 18:487–494.
15. Steuer RHD, Conis J: A new optical technique for monitoring hematocrit
and circulating blood volume: its application in renal dialysis. Dial
Transplant 1993, 22:260–265.
16. Dasselaar JJ, Huisman RM, de Jong PE, Franssen CF: Measurement of
relative blood volume changes during haemodialysis: merits and
limitations. Nephrol Dial Transplant 2005, 20:2043–2049.
17. Johner C, Chamney PW, Schneditz D, Kramer M: Evaluation of an
ultrasonic blood volume monitor. Nephrol Dial Transplant 1998, 13:
2098–2103.
18. Schneditz D, Pogglitsch H, Horina J, Binswanger U: A blood protein
monitor for the continuous measurement of blood volume changes
during hemodialysis. Kidney Int 1990, 38:342–346.
19. Steuer RR, Leypoldt JK, Cheung AK, Senekjian HO, Conis JM: Reducing
symptoms during hemodialysis by continuously monitoring the
hematocrit. Am J Kidney Dis 1996, 27:525–532.
20. Reddan DN, Szczech LA, Hasselblad V, Lowrie EG, Lindsay RM, Himmelfarb J,
Toto RD, Stivelman J, Winchester JF, Zillman LA, Califf RM, Owen WF Jr:
Intradialytic blood volume monitoring in ambulatory hemodialysis
patients: a randomized trial. J Am Soc Nephrol 2005, 16:2162–2169.
21. Andrulli S, Colzani S, Mascia F, Lucchi L, Stipo L, Bigi MC, Crepaldi M,
Redaelli B, Albertazzi A, Locatelli F: The role of blood volume reduction in
the genesis of intradialytic hypotension. Am J Kidney Dis 2002, 40:
1244–1254.
22. Barth C, Boer W, Garzoni D, Kuenzi T, Ries W, Schaefer R, Schneditz D,
Tsobanelis T, van der Sande F, Wojke R, Schilling H, Passlick-Deetjen J:
Characteristics of hypotension-prone haemodialysis patients: is there
a critical relative blood volume? Nephrol Dial Transplant 2003,
18:1353–1360.
23. Tonelli M, Astephen P, Andreou P, Beed S, Lundrigan P, Jindal K: Blood
volume monitoring in intermittent hemodialysis for acute renal failure.
Kidney Int 2002, 62:1075–1080.
24. Mitra S, Chamney P, Greenwood R, Farrington K: Linear decay of relative
blood volume during ultrafiltration predicts hemodynamic instability. Am
J Kidney Dis 2002, 40:556–565.
25. Krepel HP, Nette RW, Akcahuseyin E, Weimar W, Zietse R: Variability of
relative blood volume during haemodialysis. Nephrol Dial Transplant 2000,
15:673–679.
26. Boer W, Cremaschi L, et al: Less intradialytic complications with blood
volume control. Nephrol Dial Transplant 2002, 17(Suppl 1):127–128.
27. Damasiewicz MJ, Polkinghorne KR: Intra-dialytic hypotension and blood
volume and blood temperature monitoring. Nephrology (Carlton) 2011,
16:13–18.
Hecking et al. Trials 2012, 13:79 Page 12 of 12
http://www.trialsjournal.com/content/13/1/7928. Gabrielli D, Krystal B, Katzarski K, Youssef M, Hachache T, Lopot F, Lasseur C,
Gunne T, Draganov B, Wojke R, Gauly A: Improved intradialytic stability
during haemodialysis with blood volume-controlled ultrafiltration. J
Nephrol 2009, 22:232–240.
29. Franssen CF, Dasselaar JJ, Sytsma P, Burgerhof JG, de Jong PE, Huisman RM:
Automatic feedback control of relative blood volume changes during
hemodialysis improves blood pressure stability during and after dialysis.
Hemodial Int 2005, 9:383–392.
30. Mancini E, Santoro A, Spongano M, Paolini F, Zucchelli P: Effects of
automatic blood volume control over intradialytic hemodynamic
stability. Int J Artif Organs 1995, 18:495–498.
31. Ronco C, Brendolan A, Milan M, Rodeghiero MP, Zanella M, La Greca G:
Impact of biofeedback-induced cardiovascular stability on hemodialysis
tolerance and efficiency. Kidney Int 2000, 58:800–808.
32. Santoro A, Mancini E: Blood volume monitoring systems and
biofeedback. Contrib Nephrol 2002, 137:233–244.
33. Santoro A, Mancini E, Paolini F, Spongano M, Zucchelli P: Automatic
control of blood volume trends during hemodialysis. ASAIO J 1994,
40:M419–422.
34. Winkler RE, Patow W, Ahrenholz P: Blood volume monitoring. Contrib
Nephrol 2008, 161:119–124.
35. Wolkotte C, Hassell DR, Moret K, Gerlag PG, van den Wall Bake AW, van der
Sande FM, Kooman JP: Blood volume control by biofeedback and
dialysis-induced symptomatology. A short-term clinical study. Nephron
2002, 92:605–609.
36. Polaschegg HD: Device for treating blood in an extracorporeal system.
European Patent EP0265791, priority 16.10.1986.
37. Levin NW, Kotanko P: Is cool dialysis an effective and well-tolerated
means of reducing the frequency of intradialytic hypotension? Nat Clin
Pract Nephrol 2006, 2:670–671.
38. Selby NM, McIntyre CW: A systematic review of the clinical effects of
reducing dialysate fluid temperature. Nephrol Dial Transplant 2006,
21:1883–1898.
39. Donnan F: The theory of membrane equilibria. Chem Rev 1924, 1:73–90.
40. Stiller S, Mann H: The Donnan effect in artificial kidney therapy. Life
Support Syst 1986, 4:305–318.
41. Nolph KD, Stoltz ML, Carter CB, Fox M, Maher JF: Factors affecting the
composition of ultrafiltrate from hemodialysis coils. Trans Am Soc Artif
Intern Organs 1970, 16:495–501.
42. Locatelli F, Ponti R, Pedrini L, Di Filippo S: Sodium and dialysis: a deeper
insight. Int J Artif Organs 1989, 12:71–74.
43. Lopot F, Kotyk P, Blaha J, Valek A: Influence of the dialyzer membrane
material on sodium transport in hemodialysis. Artif Organs 1995, 19:
1172–1175.
44. Weichhart T, Kopecky C, Kubicek M, Haidinger M, Döller D, Katholnig K,
Suarna C, Eller P, Tölle M, Gerner C, Zlabinger GJ, van der Giet M, Hörl WH,
Stocker R, Säemann MD: Serum amyloid A in uremic HDL promotes
inflammation. In J Am Soc Nephrol 2012, 23:934–47.
45. Rhee EP, Souza A, Farrell L, Pollak MR, Lewis GD, Steele DJ, Thadhani R, Clish
CB, Greka A, Gerszten RE: Metabolite profiling identifies markers of
uremia. J Am Soc Nephrol 2010, 21:1041–1051.
46. Feroze U, Kalantar-Zadeh K, Sterling KA, Molnar MZ, Noori N, Benner D,
Shah V, Dwivedi R, Becker K, Kovesdy CP, Raj DS: Examining associations of
circulating endotoxin with nutritional status, inflammation, and mortality
in hemodialysis patients. J Ren Nutr 2012, 22:317–26.
47. McIntyre CW, Harrison LE, Eldehni MT, Jefferies HJ, Szeto CC, John SG, Sigrist MK,
Burton JO, Hothi D, Korsheed S, Owen PJ, Lai KB, Li PK: Circulating endotoxemia:
a novel factor in systemic inflammation and cardiovascular disease in chronic
kidney disease. Clin J Am Soc Nephrol 2011, 6:133–141.
48. Mapes DL, Lopes AA, Satayathum S, McCullough KP, Goodkin DA, Locatelli
F, Fukuhara S, Young EW, Kurokawa K, Saito A, Bommer J, Wolfe RA, Held PJ,
Port FK: Health-related quality of life as a predictor of mortality and
hospitalization: the dialysis outcomes and practice patterns study
(DOPPS). Kidney Int 2003, 64:339–349.
49. Hecking M, Kainz A, Horl WH, Herkner H, Sunder-Plassmann G: Sodium
setpoint and sodium gradient: influence on plasma sodium change and
weight gain. Am J Nephrol 2011, 33:39–48.
50. Hecking M, Karaboyas A, Saran R, Sen A, Horl WH, Pisoni RL, Robinson BM,
Sunder-Plassmann G, Port FK: Predialysis serum sodium level, dialysate sodium,
and mortality in maintenance hemodialysis patients: the dialysis outcomes
and practice patterns study (DOPPS). Am J Kidney Dis 2012, 59:238–48.51. She R: Research Randomizer (Version 3.0)., http://www.randomizer.org/.
52. Hörl WH, Koch KM, Lindsay RM, Ronco C, Winchester JF: Replacement of
renal function by dialysis. 5th edition. Dordrecht, The Netherlands: Kluwer
Academic Publishers; 2004.
53. Machek P, Jirka T, Moissl U, Chamney P, Wabel P: Guided optimization of fluid
status in haemodialysis patients. Nephrol Dial Transplant 2010, 25:538–544.
54. Chazot C, Wabel P, Chamney P, Moissl U, Wieskotten S, Wizemann V:
Importance of normohydration for the long-term survival of haemodialysis
patients. Nephrol Dial Transplant 2012, 27(6):2404–2410. Epub 2012 Jan.
55. Mailloux LU, Haley WE: Hypertension in the ESRD patient: pathophysiology,
therapy, outcomes, and future directions. Am J Kidney Dis 1998, 32:705–719.
56. Levin NW, Kotanko P, Eckardt KU, Kasiske BL, Chazot C, Cheung AK,
Redon J, Wheeler DC, Zoccali C, London GM: Blood pressure in
chronic kidney disease stage 5D-report from a kidney disease:
improving global outcomes controversies conference. Kidney Int 2010,
77:273–284.
57. Agarwal R, Weir MR: Dry-weight: a concept revisited in an effort to avoid
medication-directed approaches for blood pressure control in
hemodialysis patients. Clin J Am Soc Nephrol 2010, 5:1255–1260.
58. Heerspink HJ, Ninomiya T, Zoungas S, de Zeeuw D, Grobbee DE, Jardine MJ,
Gallagher M, Roberts MA, Cass A, Neal B, Perkovic V: Effect of lowering
blood pressure on cardiovascular events and mortality in patients on
dialysis: a systematic review and meta-analysis of randomised controlled
trials. Lancet 2009, 373:1009–1015.
59. Agarwal R, Sinha AD: Cardiovascular protection with antihypertensive
drugs in dialysis patients: systematic review and meta-analysis.
Hypertension 2009, 53:860–866.
60. Fernandez JM, Carbonell ME, Mazzuchi N, Petruccelli D: Simultaneous
analysis of morbidity and mortality factors in chronic hemodialysis
patients. Kidney Int 1992, 41:1029–1034.
61. Goldsmith DJ, Covic AC, Venning MC, Ackrill P: Ambulatory blood pressure
monitoring in renal dialysis and transplant patients. Am J Kidney Dis 1997,
29:593–600.
62. Ozkahya M, Toz H, Unsal A, Ozerkan F, Asci G, Gurgun C, Akcicek F,
Mees EJ: Treatment of hypertension in dialysis patients by
ultrafiltration: role of cardiac dilatation and time factor. Am J Kidney
Dis 1999, 34:218–221.
63. Charra B: Control of blood pressure in long slow hemodialysis. Blood Purif
1994, 12:252–258.
64. Charra B, Calemard E, Ruffet M, Chazot C, Terrat JC, Vanel T, Laurent G: Survival
as an index of adequacy of dialysis. Kidney Int 1992, 41:1286–1291.
65. Port FK, Hulbert-Shearon TE, Wolfe RA, Bloembergen WE, Golper TA,
Agodoa LY, Young EW: Predialysis blood pressure and mortality risk in a
national sample of maintenance hemodialysis patients. Am J Kidney Dis
1999, 33:507–517.
66. Li Z, Lacson E Jr, Lowrie EG, Ofsthun NJ, Kuhlmann MK, Lazarus JM, Levin
NW: The epidemiology of systolic blood pressure and death risk in
hemodialysis patients. Am J Kidney Dis 2006, 48:606–615.
67. Hecking M, Karaboyas A, Saran R, Sen A, Inaba M, Rayner H, Horl WH, Pisoni RL,
Robinson BM, Sunder-Plassmann G, Port FK: Dialysate sodium concentration
and the association with interdialytic weight gain, hospitalization, and
mortality. Clin J Am Soc Nephrol 2012, 7:92–100.
68. Lindley EJ: Reducing sodium intake in hemodialysis patients. Semin Dial
2009, 22:260–263.
69. Khan NA, Hemmelgarn BR, Tonelli M, Thompson CR, Levin A: Prognostic value
of troponin T and I among asymptomatic patients with end-stage renal
disease: a meta-analysis. Circulation 2005, 112:3088–3096.
70. Kirmizis D, Tsiandoulas A, Pangalou M, Koutoupa E, Rozi P, Protopappa M,
Barboutis K: Validity of plasma fibrinogen, D-dimer, and the von
Willebrand factor as markers of cardiovascular morbidity in patients on
chronic hemodialysis. Med Sci Monit 2006, 12:CR55–CR62.
71. Chazot C, Vo-Van C, Zaoui E, Vanel T, Hurot JM, Lorriaux C, Mayor B,
Deleaval P, Jean G: Fluid overload correction and cardiac history
influence brain natriuretic peptide evolution in incident haemodialysis
patients. Nephrol Dial Transplant 2011, 26:2630–2634.
doi:10.1186/1745-6215-13-79
Cite this article as: Hecking et al.: Blood volume-monitored regulation of
ultrafiltration in fluid-overloaded hemodialysis patients: study protocol
for a randomized controlled trial. Trials 2012 13:79.
